Last updated: April 4, 2026
Case Overview
Reckitt Benckiser Pharmaceuticals, Inc. (Reckitt) filed suit against BioDelivery Sciences International, Inc. (BioDelivery) in the District of New Jersey on September 24, 2014. The lawsuit involved allegations of patent infringement related to a transdermal drug delivery technology.
Claims and Allegations
Reckitt asserted that BioDelivery's products infringe US Patent No. 8,245,319 (the '319 patent), which covers specific formulations and methods for delivering opioids transdermally. Reckitt sought injunctive relief and damages, claiming BioDelivery's products violate its patent rights.
BioDelivery denied infringement, asserting that its formulations do not fall within the scope of the '319 patent. The defendant also challenged the patent’s validity, citing prior art and obviousness grounds.
Procedural History
- Initial Filing: September 24, 2014
- Claim Construction Phase: December 2015
- Summary Judgment Motions: Filed by both parties in 2016
- Trial Date: Initially scheduled for late 2016, but postponed multiple times
- Outcome: The case settled in 2018 before a final verdict was reached.
Key Motions and Rulings
Claim Construction
In December 2015, the court issued claim construction orders clarifying key terms such as "transdermal delivery," "penetration enhancer," and "therapeutic agent." The court adopted Reckitt's interpretations, narrowing the scope of the claims.
Infringement and Validity Contentions
In 2016, Reckitt argued that BioDelivery's BEMA system infringed the '319 patent, supported by laboratory testing and product analysis. BioDelivery countered with prior art references and expert testimony questioning the patent's novelty and non-obviousness.
Summary Judgment
Both parties moved for summary judgment. Reckitt sought judgment of infringement and validity, while BioDelivery challenged the latter. The court denied summary judgment, citing factual disputes requiring trial.
Settlement and Aftermath
In 2018, the parties settled, reaching a confidential agreement. No final court ruling on patent validity or infringement was issued.
Legal Significance
The case illustrates the importance of precise patent claims and thorough prior art analysis. It also underscores the potential for settlement in patent infringement disputes before trial outcomes are determined.
Implications for Patent Strategy
- Claim Drafting: Clarity and broadness in claim language are crucial. Narrow claims risk design-around but may limit enforcement.
- Prior Art Analysis: Early and comprehensive prior art searches can prevent invalidity defenses.
- Litigation Timing: Settlement offers can resolve disputes quickly and reduce legal expenses.
Key Resources
- US Patent No. 8,245,319
- Court Docket and Case Filings (3:14-cv-05892, District of New Jersey)
- Settlement Agreement (confidential, 2018)
Key Takeaways
- The case involved patent infringement allegations related to transdermal opioid delivery systems.
- The court clarified claim construction but did not resolve infringement or validity before settlement.
- Patent drafting and early prior art review are vital to enforceability.
- Settlement remains a common resolution in patent litigation, especially when claims are hotly contested.
- The case emphasizes the importance of detailed factual record creation for patent enforcement.
FAQs
Q1: What was the primary patent involved in the case?
A: US Patent No. 8,245,319, covering transdermal opioid delivery technology.
Q2: Did the case go to trial?
A: No, the case settled in 2018 before trial.
Q3: What were the main legal issues?
A: Patent infringement and patent validity, including claim scope and prior art considerations.
Q4: How did claim construction influence the case?
A: The court's interpretations limited the scope of infringement claims, shaping the legal arguments.
Q5: What lessons can be learned about patent litigation?
A: Precise claim drafting, thorough prior art analysis, and early case assessment improve enforcement prospects.
References
- Court docket: District of New Jersey, case 3:14-cv-05892.
- US Patent Office. (2012). US Patent No. 8,245,319.
- Court opinions and orders, 2015–2016.
